Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. P.G.M. (Peter) Mol

Publicaties

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?

Eligibility for omecamtiv mecarbil in a realworld heart failure population: Data from the Swedish Heart Failure Registry

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries

Monoclonal antibody biosimilars for cancer treatment

Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy

Real-World Evidence to Support EU Regulatory Decision Making: Results From a Pilot of Regulatory Use Cases

Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report

Lees meer

Pers/media

Towards a more efficient use of registry-based real-world data in Europe: the More-EUROPA project

Peter Mol en Patrick Vrijlandt namens Nederland in het Europese CHMP

Oratie Peter Mol over kennisuitwisseling tussen wetenschap en medicijnautoriteit